Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
2005 1
2006 1
2007 2
2008 1
2009 3
2010 2
2012 1
2013 1
2014 4
2015 3
2016 7
2017 11
2018 15
2019 13
2020 8
2021 7
2022 5
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Mazieres J, et al. Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167. Ann Oncol. 2019. PMID: 31125062 Free PMC article.
BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. ...Anonymized data were eval …
BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lun
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B. Domchek SM, et al. Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6. Lancet Oncol. 2020. PMID: 32771088 Clinical Trial.
Patients were enrolled into four initial cohorts: germline BRCA-mutated, metastatic breast cancer; germline BRCA-mutated, metastatic ovarian cancer; metastatic gastric cancer; and relapsed small-cell lung cancer. Here, we report on the cohort of patients with breast cancer …
Patients were enrolled into four initial cohorts: germline BRCA-mutated, metastatic breast cancer; germline BRCA-mutated, metastatic ovarian …
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.
Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, Brcic I, Brunner M, Cadiot G, Camara M, Christ E, Clerici T, Clift AK, Clouston H, Cobianchi L, Ćwikła JB, Daskalakis K, Frilling A, Garcia-Carbonero R, Grozinsky-Glasberg S, Hernando J, Hervieu V, Hofland J, Holmager P, Inzani F, Jann H, Jimenez-Fonseca P, Kaçmaz E, Kaemmerer D, Kaltsas G, Klimacek B, Knigge U, Kolasińska-Ćwikła A, Kolb W, Kos-Kudła B, Kunze CA, Landolfi S, La Rosa S, López CL, Lorenz K, Matter M, Mazal P, Mestre-Alagarda C, Del Burgo PM, van Dijkum EJMN, Oleinikov K, Orci LA, Panzuto F, Pavel M, Perrier M, Reims HM, Rindi G, Rinke A, Rinzivillo M, Sagaert X, Satiroglu I, Selberherr A, Siebenhüner AR, Tesselaar MET, Thalhammer MJ, Thiis-Evensen E, Toumpanakis C, Vandamme T, van den Berg JG, Vanoli A, van Velthuysen MF, Verslype C, Vorburger SA, Lugli A, Ramage J, Zwahlen M, Perren A, Kaderli RM. Nesti C, et al. Lancet Oncol. 2023 Feb;24(2):187-194. doi: 10.1016/S1470-2045(22)00750-1. Epub 2023 Jan 11. Lancet Oncol. 2023. PMID: 36640790
BACKGROUND: Awareness of the potential global overtreatment of patients with appendiceal neuroendocrine tumours (NETs) of 1-2 cm in size by performing oncological resections is increasing, but the rarity of this tumour has impeded clear recommendations to date. We aimed to assess …
BACKGROUND: Awareness of the potential global overtreatment of patients with appendiceal neuroendocrine tumours (NETs) of 1-2 cm in size by …
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors.
Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T. Robelin P, et al. J Thorac Oncol. 2019 Jun;14(6):993-1002. doi: 10.1016/j.jtho.2019.02.002. Epub 2019 Feb 13. J Thorac Oncol. 2019. PMID: 30771520 Free article. Review.
INTRODUCTION: Metastatic lung carcinoids (MLCs) remain poorly characterized and no prognostic stratification exists. ...Half of the patients had synchronous metastases, mainly located in the liver (75%), bone (42%), and lung (25%). According to WHO classification, M …
INTRODUCTION: Metastatic lung carcinoids (MLCs) remain poorly characterized and no prognostic stratification exists. ...Half of the p …
Lung cancer epigenetics: From knowledge to applications.
Duruisseaux M, Esteller M. Duruisseaux M, et al. Semin Cancer Biol. 2018 Aug;51:116-128. doi: 10.1016/j.semcancer.2017.09.005. Epub 2017 Sep 14. Semin Cancer Biol. 2018. PMID: 28919484 Review.
Lung cancer is the leading cause of cancer-related mortality worldwide. ...Immunotherapy also emerges as a major breakthrough in lung cancer treatment. However, challenges remain as a consensual approach for early lung cancer detection remains elusive while p
Lung cancer is the leading cause of cancer-related mortality worldwide. ...Immunotherapy also emerges as a major breakthrough in l
Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management.
Confavreux CB, Pialat JB, Bellière A, Brevet M, Decroisette C, Tescaru A, Wegrzyn J, Barrey C, Mornex F, Souquet PJ, Girard N. Confavreux CB, et al. Joint Bone Spine. 2019 Mar;86(2):185-194. doi: 10.1016/j.jbspin.2018.03.005. Epub 2018 Apr 6. Joint Bone Spine. 2019. PMID: 29631067 Review.
Bone is the third metastatic site after liver and lungs. Bone metastases occur in one out of three lung cancers and are usually of osteolytic aspect. Osteolytic bone metastases are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and …
Bone is the third metastatic site after liver and lungs. Bone metastases occur in one out of three lung cancers and are usually of os …
[Metastatic bronchial carcinoid tumors].
Bouledrak K, Walter T, Souquet PJ, Lombard-Bohas C. Bouledrak K, et al. Rev Pneumol Clin. 2016 Feb;72(1):41-8. doi: 10.1016/j.pneumo.2015.12.002. Epub 2016 Jan 30. Rev Pneumol Clin. 2016. PMID: 26831129 Review. French.
Bronchial carcinoids are uncommon pulmonary neoplasms and represent 1 to 2 % of all lung tumors. In early stage of disease, the mainstay and only curative treatment is surgery. ...
Bronchial carcinoids are uncommon pulmonary neoplasms and represent 1 to 2 % of all lung tumors. In early stage of disease, th …
Meditative movement for breathlessness in advanced COPD or cancer: a systematic review and meta-analysis.
Nolan CM, Brighton LJ, Mo Y, Bayly J, Higginson IJ, Man WD, Maddocks M. Nolan CM, et al. Eur Respir Rev. 2023 Jun 21;32(168):220243. doi: 10.1183/16000617.0243-2022. Print 2023 Jun 30. Eur Respir Rev. 2023. PMID: 37343961 Free PMC article. Review.
This systematic review aims to comprehensively assess the evidence on the effect of meditative movement on breathlessness (primary outcome), health-related quality of life, exercise capacity, functional performance and psychological symptoms (secondary outcomes) in advance …
This systematic review aims to comprehensively assess the evidence on the effect of meditative movement on breathlessness (primary outcome), …
Lymph Node Dissection in Thymoma: Is it worth it?
Clermidy H, Maury JM, Collaud S, Drevet G, Ginoux M, Chalabreysse L, Mornex F, Girard N, Tronc F. Clermidy H, et al. Lung Cancer. 2021 Jul;157:156-162. doi: 10.1016/j.lungcan.2021.05.022. Epub 2021 May 21. Lung Cancer. 2021. PMID: 34053783
The aim of our study was to evaluate the incidence of nodal metastasis and the short term outcomes of systematic LND in thymomas. ...In the whole population studied, nodal metastases were found in 3 patients (2.8 % of all patients) with 5.6 % in the cohort study group vs. …
The aim of our study was to evaluate the incidence of nodal metastasis and the short term outcomes of systematic LND in thymomas. ... …
Family caregiving experiences with hospice lung cancer patients compared to other cancer types.
Oliver DP, Demiris G, Benson J, White P, Wallace A, Pitzer K, Washington K. Oliver DP, et al. J Psychosoc Oncol. 2023;41(2):210-225. doi: 10.1080/07347332.2022.2101907. Epub 2022 Aug 5. J Psychosoc Oncol. 2023. PMID: 35930381 Free PMC article.
OBJECTIVES: This study seeks to compare the caregiving experience of caregivers of hospice lung cancer patients with hospice caregivers of patients with all other cancer types. METHOD: This study is based on a secondary analysis of data generated from …
OBJECTIVES: This study seeks to compare the caregiving experience of caregivers of hospice lung cancer patients with hospic
82 results